Conference on Mouse Models of Cancer

描述(由申请人提供)：该提案的目的是于2003年2月19日至23日在佛罗里达州布埃纳维斯塔湖的迪士尼当代度假区举办一次名为“癌症的老鼠模型”的科学会议。这次美国癌症研究协会(AACR)特别会议是关于这一主题的一系列非常成功的会议中的第三次。会议的主要目标是：1)由国内和国际专家对老鼠模型领域进行概述；2)重点关注老鼠模型的产生和利用方面的新技术发展；3)为对开发和利用老鼠模型进行癌症研究感兴趣的不同学科的科学家之间的互动提供一个论坛。 人类疾病的动物模型不仅对于了解影响疾病表型特征的遗传因素至关重要，而且对于开发合理的干预策略也是至关重要的。在过去的十年里，癌症小鼠模型的开发和表征出现了爆炸性的增长。第一代单等位基因癌症易感模型已经被复杂的条件TS基因敲除/转基因技术所取代，这使得能够更准确地概括人类癌症发生、发展和维持过程中的时间和空间事件。这些先进的型号目前正在与新的非侵入性成像方式相结合，以增强它们对抗肿瘤先导化合物的临床前测试的适用性。这样的系统在加速和更准确地评估进入临床之前的这些化合物方面具有重要的前景。

DESCRIPTION (provided by applicant): The aim of this proposal is to organize a scientific meeting entitled "Mouse Models for Cancer" at Disney's Contemporary Resort, Lake Buena Vista, Florida, from February 19-23, 2003. This American Association for Cancer Research (AACR) Special Conference is the third in a series of highly successful meeting on this topic. The major objectives of the meeting are: 1) to provide an overview of the field of mouse models for cancer by national and international experts; 2) To focus on new technical developments in the generation and utilization of mouse models; and 3) To provide a forum for interaction between scientists from different disciplines interested in developing and utilizing mouse models for cancer research. Animal models for human diseases are of crucial importance not only to understand the genetic factors that influence the phenotypic characteristics of the disease but also to utilize as a basis for developing rational intervention strategies. The last decade has witnessed an explosive increase in the development and characterization of mouse models for cancer. The first-generation mono-allelic cancer-prone models have been replaced by complex compound conditional TS gene knockouts/ transgenics that permit a more precise recapitulation of the temporal and spatial events in human cancer genesis, progression and maintenance. These advanced models are currently being coupled with novel noninvasive imaging modalities that enhance their suitability for preclinical testing of anti-oncologic lead compounds. Such systems hold significant promise in accelerating and making more accurate the evaluation of these compounds prior to entry into the clinic.